ATC Group: L01FA01 Rituximab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01FA01 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01F Monoclonal antibodies and antibody drug conjugates
4 L01FA CD20 (Clusters of Differentiation 20) inhibitors
5 L01FA01 Rituximab

Active ingredients in L01FA01

Active Ingredient

Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. The antigen is expressed on >95% of all B cell non-Hodgkin’s lymphomas.

Related product monographs

Document Type Information Source  
 BLITZIMA Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 REDDITUX Concentrate for solution for infusion MPI, Generic Health Products Regulatory Authority (ZA)
 RITEMVIA Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 RITUXAN Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 RUXIENCE Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 TRUXIMA Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)

United States medicines

Medicines classified under this ATC code globally

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.